Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.

Zander, ThiloThiloZanderPabst, Thomas NiklausThomas NiklausPabstSchär, SämiSämiSchärAebi, StefanStefanAebiMey, UlrichUlrichMeyNovak, UrbanUrbanNovakLerch, ErikaErikaLerchRhyner Agocs, GaëlleGaëlleRhyner AgocsGoede, JeroenJeroenGoedeManiecka, ZuzannaZuzannaManieckaHayoz, StefanieStefanieHayozRüfer, AxelAxelRüferRenner, ChristophChristophRennerDriessen, ChristophChristophDriessen2024-10-152024-10-152023-03https://boris-portal.unibe.ch/handle/20.500.12422/120489en600 - Technology::610 - Medicine & healthAlternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.article10.48350/1773553663539110.1038/s41375-023-01809-z